Abstract
It is universally agreed that dopamine is a major #neurotransmitter in
terms of reward dependence, however, there remains controversy
regarding how to modulate its role clinically to treat and prevent
relapse for both substance and non-substance-related #addictivebehaviors.
It is also agreed by most that there is a need to provide early genetic
identification possibly through a novel researched technology referred
to
Genetic Addiction Risk Score(GARS).™ The existing #FDA-approved medications promote blocking dopamine, however, we argue that a more
prudent paradigm shift should be biphasic-short-term blockade and
long-term upregulation, enhancing functional connectivity of brain
reward.
It is critical to understand that the real phenotype is not any specific
drug or non –drug addictive behavior, but instead is Reward Deficiency
#Syndrome (RDS). Thus the true phenotype of all addictive behaviors is
indeed RDS. Finally, we are suggesting that one way to combat the
current out of control Opioid /Alcohol crisis worldwide is to seriously
reconsider treating RDS by simply supplying powerful narcotic agents
(e.g. #Buprenorphine). This type of treatment will only keep people
addicted. A more reasonable solution involving genetic testing, urine
drug
screens using Comprehensive Analysis of Reported Drugs (CARD) and
dopamine homeostasis we call “ Precision Addiction Management” ™
seems parsonomiuos.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.